Jade Biosciences, Inc.
JBIO
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.3B
Close$
$2.80
88.1% downside
Current Fair Value
88.1% downsideOvervalued by 88.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.30 Billion |
|---|---|
| Enterprise Value | $1.19 Billion |
| Dividend Yield | $2.40 (-) |
| Earnings per Share | $-4.06 |
| Beta | 1.49 |
| Outstanding Shares | 61,050,775 |
Return
| Return on Equity | -42.94% |
|---|---|
| Return on Assets | -40.01% |
| Return on Invested Capital | -42.44% |
Valuation & Multiples
| P/E Ratio | -7.76 |
|---|---|
| PEG | -10.55 |
| Price to Sales | - |
| Price to Book Ratio | 3.35 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -6.38 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.66
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.73
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.9341▼ 431.00% |
|---|---|
| Total Calls | 35,900▲ 220.54% |
| Total Puts | 69,434▼ 0.71% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 126.30%▲ 40.03% |
|---|---|
| Total Invested | $1.62B▲ 131.42% |
| Investors Holding | 157▲ 34.00% |
ESG Score
No data
About Jade Biosciences, Inc.
50 employees
CEO: Tom Frohlich Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) ...